Basal Cell Carcinoma (BCC) is the most common type of cancer among the white population. Individuals with fair skin have an average lifetime risk of around 30% for developing BCC, and there is a noticeable upward trend in its incidence rate. The principal treatment objectives for BCC involve achieving the total excision of the tumor while maximizing the preservation of function and cosmesis. Surgery is considered the treatment of choice for BCC for two main reasons: it allows for the highest cure rates and facilitates histological control of resection margins. However, in the subgroup of patients with low-risk recurrence or medical contraindications for surgery, new non-surgical treatment alternatives can provide an excellent oncological and cosmetic outcome. An evident and justified instance of these local therapies occurred during the COVID-19 pandemic, a period when surgical interventions carried out in hospital settings were not a viable option.
基底细胞癌（BCC）是白种人群中最为常见的癌症类型。肤色较浅的个体罹患基底细胞癌的终生风险平均约为30%，且其发病率呈现显著上升趋势。基底细胞癌的主要治疗目标在于实现肿瘤的完整切除，同时最大限度地保留功能与美观效果。手术被视为基底细胞癌的首选治疗方案，主要基于两方面原因：其可实现最高的治愈率，并有助于对切除边缘进行组织学控制。然而，对于低复发风险或存在手术医学禁忌症的患者亚群，新型非手术治疗方案能够提供优异的肿瘤学与美容学效果。在COVID-19大流行期间，这些局部疗法得到了明确且合理的应用实例——当时在医院环境中实施外科手术并非可行选择。
Topical and Intralesional Immunotherapy for the Management of Basal Cell Carcinoma
肿瘤(癌症)患者之家